TC BioPharm Announces $ 4 Million Public Offering Prices News

EDINBURGH, SCOTLAND, June 2, 2022 / PRNewswire / – TC BioPharm (Holdings) PLC (“TC BioPharm” or “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical biotechnology company developing a platform to treat cancer using allogeneic gamma-delta T-Cells today announced the price of a secured public offering of 10,000,000 U.S. Depositary Shares (“ADS”), each representing one common share of the company, at a public offering price. $ 0.40 per ADS, for total gross revenue in the amount $ 4 million, before deducting discounts and underwriting commissions, as well as other costs per offer. In addition, the Company has provided underwriters with a 45-day option to purchase an additional 1,500,000 advertisements at a public offering price per share, less discounts and underwriting fees, to cover excess allocations, if any.

The proposal is expected to close or approx June 7, 2022subject to normal closure conditions.

EF Hutton, a division of Benchmark Investments, LLC, acts as the sole book sales manager.

An application for registration in Form F-1 (file № 333-265159) was submitted to the Securities and Exchange Commission (“SEC”) and was declared effective in June. [2]2022. The final prospectus concerning the proposal will be submitted to the SEC and will be available on the SEC website at Electronic copies of the final prospectus relating to this offer, if available, are available from EF Hutton, a division of Benchmark Investments, LLC, 590 Madison Avenue, 39th Floor, New York, New York 10022, Attention: Syndicate Department, or by email at or by calling (212) 404-7002.

This press release does not constitute an offer to sell or request to purchase any of the securities described in this document, nor will it sell those securities in any state or jurisdiction in which such an offer, petition or sale would be illegal prior to registration or qualification under the securities laws of any such state or jurisdiction.

About TC BioPharm (Holdings) PLC

TC BioPharm is a clinical-based biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta-T cell therapy for cancer treatment with evidence of efficacy in humans in acute myeloid leukemia. Gamma-delta T cells are natural immune cells that embody the properties of both the innate and adaptive immune systems and can essentially distinguish between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and modified CAR gamma-delta cells to effectively identify, target, and eliminate both liquid and solid tumors in cancer.

TC BioPharm is a leader in the development of gamma-delta-T cell therapy and the first company to conduct phase II / major clinical trials in oncology. The company is conducting two clinical trials at the initiative of researchers for its unmodified line of gamma-delta T-cell products – phase 2b/ 3 is OmnImmune®’s main study in the treatment of acute myeloid leukemia and the Phase 1 study for ImmuniStim in the treatment of patients with Covid using the company’s patented allogeneic technology CryoTC to deliver frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications for solid tumors, as well as a significant portfolio of IP / patents in the use of CARs with gamma-delta cells and owns its own production to maintain cost and product quality control.

Statements about the future

This press release may contain forward-looking statements concerning future events. These forward-looking statements are subject to inherent uncertainty in forecasting future results and conditions. These statements reflect our current beliefs, and a number of important factors may lead to the fact that the actual results differ significantly from those expressed in this press release. We make no commitment to review or update any forward-looking statements as a result of new information, future events or otherwise. A link to the BioPharm TC website has been provided for convenience, and the information contained on such site is not included in this press release by reference.

See original content for multimedia downloads:

SOURCE of TC BioPharm

Source link